Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2020-09-11
- Target Recruit Count
- 200
- Registration Number
- NCT04395768
- Locations
- 🇦🇺
National Institute of Integrative Medicine, Melbourne, Victoria, Australia
Hydroxychloroquine in COVID-19 Patients
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Samah Lutfy
- Target Recruit Count
- 200
- Registration Number
- NCT04394442
- Locations
- 🇸🇦
SNH, Mecca, Saudi Arabia
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Fundacion GenesisCare
- Target Recruit Count
- 15
- Registration Number
- NCT04394182
- Locations
- 🇪🇸
Hospital La Milagrosa, GenesisCare, Madrid, Spain
🇪🇸Hospital Vithas Valencia Consuelo, Valencia, Spain
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Centenario Hospital Miguel Hidalgo
- Target Recruit Count
- 108
- Registration Number
- NCT04391127
- Locations
- 🇲🇽
Jose Manuel Arreola Guerra, Aguascalientes, Mexico
Antimalarial and Covid 19 in Rheumatoid Arthritis
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT04389320
- Locations
- 🇪🇬
Manal Hassanien, Assiut, Yes, Egypt
TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Università Politecnica delle Marche
- Target Recruit Count
- 116
- Registration Number
- NCT04390061
Favipiravir vs Hydroxychloroquine vs Control in COVID -19
- Conditions
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 150
- Registration Number
- NCT04387760
- Locations
- 🇧🇭
Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
LY3214996 +/- HCQ in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Kimberly Perez, MD
- Target Recruit Count
- 52
- Registration Number
- NCT04386057
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
- Target Recruit Count
- 800
- Registration Number
- NCT04385264
- Locations
- 🇨🇭
Unisanté, Lausanne, Vaud, Switzerland
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-10-06
- Target Recruit Count
- 400
- Registration Number
- NCT04384458
- Locations
- 🇧🇷
Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.